Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNV3 + toripalimab + chemotherapy in checkpoint inhibitor-failed advanced melanoma
ChiCTR2400091269Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DNV3 and toripalimab in melanoma, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
DNV3toripalimab
03
Conditions
melanoma
Beyond the preview
Go deeper on ChiCTR2400091269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091269.